Trial Profile
Phase II Study of SOX in Patients With Platinum-resistant Nasopharyngeal Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 29 Jul 2011 New trial record